Clinical Trial News and Research

RSS

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

Acorda third quarter GAAP net income increases to $18.9 million

Acorda Therapeutics, Inc. today announced its financial results for the third quarter ended September 30, 2011.

4 Nov 2011

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

CRF summit to examine importance of gender in cardiovascular disease research

"In Pursuit of Excellence: Improving Cardiovascular Outcomes in Women" will be held on Friday Dec. 9, 2011. The meeting, which will bring together top national experts in research, academia, and health policy to examine the importance of gender in cardiovascular disease research, will take place at The Princeton Club in New York City. Roxana Mehran, MD will Chair this important meeting.

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Quintiles receives two awards for clinical research

Quintiles' digital efforts to bridge the gaps between clinical research, patients and clinical trial participants have been recognized in the form of two International Davey Awards and a Web Health Award this week.

4 Nov 2011

Penn research group receives NCI grant to establish BETRNet

A research group at the Perelman School of Medicine of the University of Pennsylvania, led by John Lynch, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology, has received a National Cancer Institute (NCI) grant to establish a Barrett's esophagus translational research network (BETRNet) with Columbia University and the Mayo Clinic.

4 Nov 2011

Edwards Life Sciences heart valve approved in the US

The U.S. Food and Drug Administration (FDA) this Wednesday approved the sale of Edwards Life Sciences Corp's Sapien heart valve for patients deemed too sick to have open-heart surgery.

3 Nov 2011

Columbia Laboratories third quarter total net revenues decrease to $4.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2011.

3 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.

3 Nov 2011

Clinical-grade viral vector can cure choroideremia

Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness that affects mainly males.

3 Nov 2011

Ivacaftor drug improves lung function in people with cystic fibrosis

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.

3 Nov 2011

Medtronic initiates CoreValve System trial to treat severe aortic stenosis in Japan

Medtronic, Inc. today announced the first implant in a clinical trial in Japan that will evaluate the safety and effectiveness of the Medtronic CoreValve System.

From Medtronic 3 Nov 2011

Argus II Retinal Prosthesis System successfully implanted in advanced Retinitis Pigmentosa patient

Second Sight Medical Products, Inc., the world's leading developer of retinal prostheses for the blind, announced that the first ever commercial implantation of such a prosthesis was successfully completed on Saturday, October 29th in Pisa, Italy.

2 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011

Zalicus third quarter revenue increases to $2.4 million

Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.

2 Nov 2011

Vitamin D does not confer benefits against mortality in postmenopausal women

Doctors agree that vitamin D promotes bone health, but a belief that it can also prevent cancer, cardiovascular disease and other causes of death has been a major health controversy. Consistent with advice issued last fall by the Institute of Medicine, a new study finds that vitamin D did not confer benefits against mortality in postmenopausal women after controlling for key health factors such as abdominal obesity.

2 Nov 2011